InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (6 ops.)
Explore the complete record of transactions filed by Zalevsky Jonathan, Directeur de la Recherche et du Développement. Insider active across 2 companies, notably NEKTAR THERAPEUTICS. In total, 11 disclosures have been published. Total volume traded: €1.3m. The latest transaction was filed on 15 May 2022 — Attribution. Regulator: SEC (Form 4). All data is openly available.
Declarations11 total
023,950 shares0
Common Stock
SEC:0001209191-22-029905:0·
€105,21110,912 shares@ €9.64180.0044% mcap12.3% of flow
Common Stock
SEC:0001209191-22-011442:0·
€105,21110,912 shares@ €9.64180.0044% mcap53.9% of flow
Common Stock
SEC:0001209191-22-011442·
052,950 shares0
Common Stock
SEC:0001209191-21-070697·
052,950 shares0
Common Stock
SEC:0001209191-21-070697:0·
040,150 shares0
Common Stock
SEC:0001209191-21-065229·
040,150 shares0
Common Stock
SEC:0001209191-21-065229:0·
€89,9547,662 shares@ €11.74030.0038% mcap46.1% of flow
Common Stock
SEC:0001209191-21-052395·
€89,9547,662 shares@ €11.74030.0038% mcap10.5% of flow
Common Stock
SEC:0001209191-21-052395:0·
€468,32131,111 shares@ €15.0532100.0% of flow
Common Stock
SEC:0001209191-21-034191·
€468,32131,111 shares@ €15.05320.020% mcap54.5% of flow
Common Stock
SEC:0001209191-21-034191:0·
11 of 11 declarations
About Zalevsky Jonathan
Jonathan Zalevsky is the Chief R&D Officer at Nektar Therapeutics. He is responsible for innovation and the development of new treatments within the company.
